There are several research clinics and institutes that are seeking participants for their studies and clinical trials right now! Please see below to find a clinical trial that appropriate for you. Also, if you have specific questions about clinical trials that might be appropriate for you, please reach out to our PNW Chapter Clinical Trial Education Volunteers (CTEV) Laura Tremblay (LDTremblay71@gmail.com) and/or Jude Restis (JRestis@yahoo.com).
BENAROYA RESEARCH INSTITUTE – SEATTLE
If interested in any of these studies or have any questions, please contact: diabetes@benaroyaresearch.org, 1-800-888-4187.
βETA PRESERVE Study
This study is looking at how an investigational study drug, called teplizumab, might possibly help protect insulin producing cells by affecting the immune cells that attack them.
You may be eligible for this study if you:
- Are 8 – 25 years old
- Have been diagnosed with T1D within the past month
This study is also enrolling at Rocky Mountain Clinical Research – Idaho Falls (below).
FABULINUS Study
This study is testing an investigational drug called frexalimab in people with newly-diagnosed T1D. Frexalimab is thought to work by blocking pathways of immune cell activation and function.
You can help researchers understand:
- If frexalimab can preserve the body’s own insulin production.
- If frexalimab can help the body control blood glucose levels.
- If frexalimab can decrease the dose of insulin.
- How safe frexalimab is.
You may be eligible for this study if you are:
- Age 12-21 years old
- Newly-diagnosed with T1D in the past 3 months
This study is also enrolling at Rocky Mountain Clinical Research – Idaho Falls (below).
BRIDge Biorepository Study
The Diabetes Biorepository is a confidential list of people with type 1 diabetes (T1D) who donate samples and provide health information for scientific research. This library of samples and information helps BRI’s scientists study how and why T1D starts and make progress toward prevention and better treatments.
Qualifications:
- Diagnosed with T1D
- Over 1-year old
- Live in, or regularly travel to Seattle
Read more about this study here, through an interview with Megan Smithmyer, PhD, Staff Scientist at Benaroya Research Institute in the Center for Interventional Immunology.
If you are further interested in BRIDge or any of BRI’s biorepositories, you can complete an interest form online here and their team will reach out to you.
ROCKY MOUNTAIN CLINICAL RESEARCH – IDAHO FALLS
βETA PRESERVE Study
This study is looking at how an investigational study drug, called teplizumab, might possibly help protect insulin producing cells by affecting the immune cells that attack them.
You may be eligible for this study if you:
- Are 8 – 25 years old
- Have been diagnosed with T1D within the past month
If interested in βETA PRESERVE, please contact rockymountainclinicalresearch@idahomed.com, 208-522-6005
This study is also enrolling at Benaroya Research Institute – Seattle (above).
FABULINUS
Rocky Mountain Clinical Research Center in Idaho Falls is another site for the FABULINUS trial. This trial is testing how well an investigational study drug preserves pancreatic beta cell function in people recently diagnosed with type 1 diabetes. Study participants will continue their insulin therapy and will have their glucose monitored throughout the study in accordance with the study protocol. Researchers hope to see if the investigational study drug can help people with T1D better control their glucose levels.
Participants will receive at no cost: study product or placebo, a continuous glucose monitor, an electronic diary, a blood glucose meter, study visits and study-specific procedures.
The study length is 2.5 years.
You may be eligible for this trial is you are:
- Age 12-21 years old
- Newly diagnosed with T1D and on insulin therapy for 90 days or less
If interested in FABULINUS, please contact Clive Harston, clive.harston@rmclinicalresearch.com, 208-528-9657.
DIAGNODE-3
The purpose of this phase 3 study is to explore whether an investigational drug, Diamyd® (rhGAD65), is able to preserve the body’s own insulin-producing ability. Diamyd® prevents attack on the body’s insulin-producing beta cells by reprogramming the immune system to ignore GAD (glutamic acid decarboxylase). In T1D, GAD can give rise to autoantibodies, which tell the immune system to destroy beta cells. Over a two-month period, participants will receive three ultrasound-guided injections into a lymph node located in the groin, followed by a 22-month follow-up. For every two participants receiving Diamyd®, one will receive a placebo (a treatment with no therapeutic effect for comparison).
You may be eligible for this study if you:
- Are 12-28 years old
- Were diagnosed with T1D within the last 6 months
- Have GAD autoantibody
- Have a specific genetic marker (HLA DR3-DQ2)
You can find out more about this study here. If interested in DIAGNODE-3, please contact Joann Malone, joann.malone@rmclinicalresearch.com, 208-528-9650.
ONWARDS 11 Study
This study is comparing the safety and efficacy of once weekly icodec long-acting insulin versus once daily glargine (Lantus) long-acting insulin, both in combination with fast-acting insulin aspart (Novolog).
You may be eligible for this study if you:
- Are 18 years or older
- Have been diagnosed with T1D for at least one year
- Have an A1C 7.0%-10.0%
- Have been using multiple daily injections (MDIs) for at least 6 months before screening
If interested in ONWARDS 11, please contact rockymountainclinicalresearch@idahomed.com, 208-522-6005
This study is also enrolling at Rainier Clinical Research Center – Renton (below).
OHSU – PORTLAND
SUGARNSALT
This trial is determining if an investigational oral medication called Sotagliflozin (SOTA) can help slow kidney function decline in patients with type 1 diabetes. SOTA is a drug in the family of medications called SGLT1 and SGLT2 (sodium/glucose transport) inhibitors and is currently approved by the FDA to reduce the risk of being admitted to the hospital due to heart failure in persons with type 2 diabetes and other conditions. Some studies have shown that drugs like SOTA may also slow the progression of kidney disease in people with and without diabetes.
You may be eligible to participate if you are:
- Diagnosed with type 1 diabetes for at least 8 years and continuously treated with insulin
- Between the ages of 18 and 75 years
- Have been told by your doctor that you have diabetic kidney disease or protein in your
urine
If you are interested in participating in this trial, please contact OHSU study staff (Aly Carlson or Krista Metas) by phone or email:
Aly Carlson: 971-610-3005
Krista Metas: 971-484-5758
Email: sugarnsalt@ohsu.edu
UNIVERSITY OF WASHINGTON – SEATTLE
REMODEL T1D
REMODEL T1D is looking at the potential benefits of the GLP-1 agonist, Semaglutide, on kidney function in people with abnormal kidney function due to T1D. A secondary objective is to study the glycemic effects of Semaglutide in people with T1D. The study will last 26 weeks, including a gradual titration of study medications to maximum target dose over 12 weeks, followed by evaluation of the effect of Semaglutide on the kidney. Evaluation will include kidney MRI, urine testing and blood testing.
You may be eligible for this study if you:
- Are 18 years of age or older
- Have been diagnosed with T1D for at least 5 years
- Have abnormal kidney function due to T1D
- Are on stable doses of medications for blood pressure and cholesterol
If interested, please contact: Darinka Gil, dgm91@uw.edu
T1-DISCO – Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
The purpose of this study is to learn more about the effects of an investigational drug called semaglutide (Ozempic™), as a safe and effective means of improving cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. Semaglutide is considered investigational because it is an FDA-approved drug being used off-label. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way. UW will perform a randomized study to assess the effects of 8 months of once weekly subcutaneous semaglutide vs. once weekly placebo injections. If participants join the study, they will have one screening visit, one 8-month treatment phase, two long study visits, two MRI visits, four interim visits, and one follow-up visit over approximately 9 months. They will be asked to take the study medication or a placebo, for a period of 8 months.
If interested, please contact: Bri Hihara, bhihara@uw.edu
SUGARNSALT
This study involves taking a tablet of sotagliflozin (SOTA) or an identical tablet without any active drug (200 mg) every day for about 3 years and 4 months. The study involves 19 study visits including one that can be done over the phone. SOTA is currently approved to reduce the risk of being admitted to the hospital due to heart failure, or dying of cardiovascular disease, in persons with type 2 diabetes and other conditions. SOTA is not currently approved to improve glycemic control in patients with type 1 diabetes. SOTA is also not currently approved to slow progression of kidney disease in diabetes. However, the FDA has reviewed this study and has granted the investigators permission to use SOTA to investigate whether it can have a beneficial effect on kidney function in type 1 diabetes.
Participants will receive $50 for each study visit, except visit 5, which is a short visit done at the same time as visit 4 or as a brief telephone call. If interested, please contact: Paul Ly, lypaul@uw.edu
INHALE AID Ex Study
INHALE AID Ex is an inhale insulin study for those with T1D on Tandem t:slim X2 insulin pump with control-IQ. The study wants to see if inhale insulin given for a meal is safer and better to use than a bolus of insulin through the pump when exercise follows a meal. About 30 people will be in the study at 3 sites in the U.S.
You may be eligible for this study if you:
- Have Type 1 Diabetes and are between 18 and 60 years of age
- Use a Tandem insulin pump with Control IQ
- Are physically active, currently doing exercise sessions
- Can complete a 45-minutes brisk walk on a treadmill
- Would like to help us determine if taking inhaled insulin at mealtime causes less low blood sugar during exercise compared to Novolog or Humalog
Can you attend 4 visits in clinic? Compensation for your time and travel provided.
If interested, please contact: Jessica Baran, jbaran@uw.edu
CATT1 Study
The CATT1 Study will look at whether the study drug, cadisegliatin (also called TTP339), can reduce the frequency of low blood sugar (hypoglycemia) in adults with type 1 diabetes. The study drug is a tablet taken by mouth. It is designed to stimulate the liver and improve the liver’s ability to store sugar from food, which may reduce episodes of high or low blood sugar.
You may be eligible for this study if you:
- Are at least 18 years old
- Need help managing your low blood sugar from type 1 diabetes
If interested, please contact: Darinka Gil, dgm91@uw.edu
SEATTLE CHILDREN’S HOSPITAL
MANATEE T1D
Metformin and Automated Insulin Delivery system effects on renal vascular resistance, insulin sensitivity, and cardiometabolic function in youth with type 1 diabetes.
This study is a randomized, double-blind, placebo-controlled trial being conducted at Seattle Children’s Hospital. The purpose of this study is to learn about the health effects on the kidney, blood vessels, and insulin sensitivity of combining two treatments – an automated insulin delivery system and metformin – for people ages 12-25 years old who have had type 1 diabetes for at least 6 months. The use of metformin in this study is experimental. Study participants will be randomized to receive metformin or a placebo for the study period of 4 months.
If interested, please contact: Kevin Bocek, Kevin.Bocek@seattlechildrens.org; Bentina Marin, bentina.marin@seattlechildrens.org.
RAINIER CLINICAL RESEARCH CENTER – RENTON
If you are interested in one or more of the trials below or have any questions, please contact the Site Coordinator at RCRC at recruitment@rainier-research.com or call 888-478-8343.
SURPASS-T1D-1 (Eli Lilly Tirzepatide (Mounjaro Study)
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks. Diabetes education will be provided and participants will have access to personnel who have experience in providing diabetes and lifestyle management counseling at baseline and throughout the study duration, according to local standards.
You may be eligible for this study if you:
- Are 18 years or older
- Have an HbA1C of 7.0-10.5% at the time of screening
- Have a BMI > 25
OPT-200
This study is looking to explore the effects of subcutaneous study medication on sustaining or increasing C-peptide production in those diagnosed with T1D. The study medication blocks a major mechanism of the immune attack on beta cells. C-peptide levels are a by-product of insulin production. When insulin production rises, C-peptide levels increase. Part B of the study is currently enrolling. Participants may receive study drug or placebo with a total participation of 48 weeks.
You may be eligible for the Part B enrollment group if you:
- Are 18-50 years old
- Have been diagnosed in the last 1-10 years
ONWARDS 11 Study
This study is comparing the safety and efficacy of once weekly icodec long-acting insulin versus once daily glargine (Lantus) long-acting insulin, both in combination with fast-acting insulin aspart (Novolog).
You may be eligible for this study if you:
- Are 18 years old or older
- Have been diagnosed with T1D for at least one year
- Have an A1C of 7.0-10.0%
- Have been using multiple daily insulin injections (MDIs) for at least 6 months before screening
This study is also enrolling at Rocky Mountain Clinical Research – Idaho Falls (above).
INFLUENZA Study
This study is looking to see how well a Novel Long-Acting Antiviral Conjugate product prevents symptomatic influenza infections compared to placebo. Participants are ENCOURAGED to receive a standard flu vaccine either at least 2 weeks before starting the study, or a recombinant flue vaccine any time after the study has begun. The study will last approximately 7 months.
You may be eligible for this study if you:
- Are 12 years old or older
- Have been diagnosed with T1D
FREESTYLE LIBRE CGM Study
This study is evaluating the safety and accuracy of the Freestyle Libre CGM when worn for 31 days. The goal is to improve diabetes care and technology for everyone who depends on it. Participating in this study will help advance diabetes technology and care, while receiving cutting-edge CGM devices at no cost. This study requires 7 clinic visits, including four 12-hour frequent sampling visits. Compensation is $3,325 for completion of study visits.
You may be eligible for this study if you:
- Are an adult (18+) who has been diagnosed with Type 1 or Type 2 diabetes
- Are currently using insulin therapy (must be a pump or at least 3 daily injections)
- Are willing to use a CGM device during the study period
Medtronic
This study is looking at a next generation Medtronic algorithm. The objective is to reduce diabetes management burdens around meals and general device use. The study will involve a 3-4 week run-in, followed by a ~3 month study period. You must be at least 18 years old to participate.
Find a Clinical Trial Near You!
If the above clinical trials and studies don’t work for you, you can utilize Breakthrough T1D and Antidote’s Clinical Trial Connection Tool to find one that resonates with you! To utilize this tool visit this link, or if you want to learn more about Clinical Trials in general, visit here.
